Spectral Medical Valuation
Is EDT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EDT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EDT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EDT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EDT?
Key metric: As EDT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is EDT's PB Ratio? | |
|---|---|
| PB Ratio | -4.8x |
| Book | -CA$31.28m |
| Market Cap | CA$149.89m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 78.5x |
| Enterprise Value/EBITDA | -13.1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does EDT's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.7x | ||
EPRX Eupraxia Pharmaceuticals | 13.1x | n/a | CA$174.9m |
MDNA Medicenna Therapeutics | 6.1x | 60.2% | CA$122.7m |
ONC Oncolytics Biotech | 11.3x | 37.5% | CA$102.5m |
MSCL Satellos Bioscience | 4.1x | -15.1% | CA$85.2m |
EDT Spectral Medical | n/a | n/a | CA$149.9m |
Price-To-Book vs Peers: EDT has negative equity and a Price-To-Book Ratio (-4.8x) compared to the peer average (8.7x).
Price to Book Ratio vs Industry
How does EDT's PB Ratio compare vs other companies in the CA Biotechs Industry?
Price-To-Book vs Industry: EDT has negative equity and a Price-To-Book Ratio (-4.8x) compared to the Canadian Biotechs industry average (2.8x).
Price to Book Ratio vs Fair Ratio
What is EDT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -4.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate EDT's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fennec Pharmaceuticals
US$145.9m
Operates as a biopharmaceutical company in the United States.
FRX
US$7.35
7D
29.4%
1Y
-35.8%
Verano Holdings
CA$722.2m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$1.98
7D
-17.2%
1Y
-65.9%
Medexus Pharmaceuticals
CA$60.4m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.45
7D
9.4%
1Y
69.0%